Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 / G蛋白偶联受体/G蛋白 / 腺苷受体 / Ciforadenant

Ciforadenant {[allProObj[0].p_purity_real_show]}

货号：A186100 同义名： CPI-444;V81444 Ambeed 开学季，买赠积分，赢豪礼

CPI-444 is an orally administered antagonist of the adenosine A2A receptor. Upon oral administration, CPI-444 binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs).

Ciforadenant 化学结构 CAS号：1202402-40-1
Ciforadenant 化学结构
CAS号：1202402-40-1
Ciforadenant 3D分子结构
CAS号：1202402-40-1
Ciforadenant 化学结构 CAS号：1202402-40-1
Ciforadenant 3D分子结构 CAS号：1202402-40-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Ciforadenant 纯度/质量文件 产品仅供科研

货号：A186100 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• JACS Au, 2024. Ambeed. [ A148168 ]
• JMC, 2024. Ambeed. [ A187643 ]
• JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
• Biomacromolecules, 2024. Ambeed. [ A110759 ]
• Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 Adenosine Receptor ↓ 其他靶点 纯度
ZM241385 ✔ {[allProObj[0].p_purity_real_show]}
Istradefylline +++

Adenosine A2A receptor, Ki: 2.2 nM

 		{[allProObj[0].p_purity_real_show]}
Reversine +

human A3 adenosine receptor, Ki: 0.66 μM

 		{[allProObj[0].p_purity_real_show]}
SCH58261 ++++

bovine A2a, Ki: 2.0 nM

rat A2a, Ki: 2.3 nM

 		{[allProObj[0].p_purity_real_show]}
A2A receptor antagonist 1 ++

A1R, Ki: 264 nM

A2AR, Ki: 4 nM

 		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Ciforadenant 生物活性

描述 Adenosine signaling through the A2A adenosine receptor(A2AR) on immune cells is a critical regulator of inflammation and immune response which has been shown to suppress antitumor immunity and limit the efficacy of immunotherapy, chemotherapy, adoptive cell transfer therapies, and vaccines in preclinical models. CPI-444 is an orally administered antagonist of the A2AR with a Ki of 3.54 nM. C57BL/6 mice immunized with vaccinia-OVA showed a signifcant enhancement in the antigen-specifc CD8+ T cell response when treated with CPI-444 (10 mg/kg, p.o. daily for 5 days starting 1 day post-infection) compared with models[2]. Anti-PD-1 and CPI-444(100 mg/kg, 12 days) combination treatment showed a significant improvement in tumor regression and animal survival in both CT26 and MC38 tumor models, compared with anti-PD-1 treatment alone. Phase 1b clinical trial in patients with non-small cell lung, melanoma, renal, triple negative breast, and other (head and neck, colorectal [MSI-H], bladder) tumors demonstrated that NECA(adenosine analog) signaling was robustly inhibited at the doses selected in CPI-444 treatment[3].

Ciforadenant 动物研究

Dose Mice: 1 mg/kg - 100 mg/kg[1] (p.o.)
Administration p.o.

Ciforadenant 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03708224 Cancer Carcin... 展开 >>oma Squamous Cell Carcinoma Head and Neck Cancer 收起 << Phase 2 Not yet recruiting November 30, 2025 United States, California ... 展开 >> University of San Francisco, California San Francisco, California, United States, 94115 收起 <<
NCT03337698 Carcinoma, Non-Small-Cell Lung Phase 1 Phase 2 Recruiting April 20, 2022 United States, Connecticut ... 展开 >> Smilow Cancer Hospital at Yale New Haven Recruiting New Haven, Connecticut, United States, 06510 United States, Massachusetts Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, New York Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749 Recruiting New York, New York, United States, 10032 United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Australia, Victoria Peter Mac Callum Cancer Center Recruiting East Melbourne, Victoria, Australia, 3002 France Centre Léon Bérard Recruiting Lyon, France, 69008 Hôpital Nord Not yet recruiting Marseille, France, 13915 Institut Universitaire du Cancer de Toulouse-Oncopole; PHARMACIE Recruiting Toulouse, France, 31100 Korea, Republic of Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Severance Hospital, Yonsei University Health System; Pharmacy Recruiting Seoul, Korea, Republic of, 03722 University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC) Recruiting Songpa-gu, Korea, Republic of, 05505 Spain Clínica Universidad de Navarra Recruiting Pamplona, Navarra, Spain, 31620 Hospital Universitari Vall d'Hebron Recruiting Barcelona, Spain, 08035 Fundación Jimenez Díaz Recruiting Madrid, Spain, 28040 South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro Recruiting Madrid, Spain, 28050 United Kingdom Barts Cancer Institute Recruiting London, United Kingdom, E1 2AT Royal Marsden Hospital; Institute of Cancer Research Recruiting Sutton, United Kingdom, SM2 5PT 收起 <<
NCT03454451 Non-Small Cell Lung Cancer ... 展开 >> Renal Cell Cancer Colorectal Cancer Triple Negative Breast Cancer Cervical Cancer Ovarian Cancer Pancreatic Cancer Endometrial Cancer Sarcoma Squamous Cell Carcinoma of the Head and Neck Bladder Cancer Metastatic Castration Resistant Prostate Cancer 收起 << Phase 1 Recruiting December 2023 United States, Connecticut ... 展开 >> Yale School of Medicine Recruiting New Haven, Connecticut, United States, 06519 Contact: Site Coordinator    203-785-3482    ycci@yale.edu    Principal Investigator: Patricia LoRusso, MD          United States, Florida University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Study Coordinator    305-243-0865    txl351@med.miami.edu    Principal Investigator: Jaime Merchan, MD          United States, Illinois The University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Site Coordinator    773-702-1835    mweist@medicine.bsd.uchicago.edu    Principal Investigator: Jason Luke, MD          United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Contact: Site Coordinator    212-824-7309    ccto@mssm.edu    Principal Investigator: Thomas Marron, MD          United States, North Carolina Carolina BioOncology Institute Recruiting Huntsville, North Carolina, United States, 28078 Contact: Study Coordinator    704-947-6599    info@carolinabiooncology.org    Principal Investigator: John Powderly          United States, Oklahoma University of Oklahoma - Stephenson Cancer Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Site Coordinator    405-271-1112    SCC-Clinical-Trials-Office@ouhsc.edu    Principal Investigator: Abhishek Tripathi, MD          United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Site Coordinator    615-329-7274    asksarah@sarahcannon.com    Principal Investigator: Melissa Johnson, MD          United States, Texas Mary Crowley Cancer Research Recruiting Dallas, Texas, United States, 75230 Contact: Study Coordinator    972-566-3000    information@marycrowley.org    Principal Investigator: Minal Barve, MD          United States, Wisconsin Froedtert Hospital & Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Site Coordinator    414-805-8900    CCCTO@mcw.edu    Principal Investigator: Matthew Riese, MD 收起 <<

Ciforadenant 参考文献

[1]Willingham SB, Ho PY, et al. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models. Cancer Immunol Res. 2018 Oct;6(10):1136-1149.

[2]Leone RD, Sun IM, Oh MH, Sun IH, Wen J, Englert J, Powell JD. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother. 2018 Aug;67(8):1271-1284. doi: 10.1007/s00262-018-2186-0. Epub 2018 Jun 19. PMID: 29923026.

[3]Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies

Ciforadenant 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.45mL

0.49mL

0.25mL

12.27mL

2.45mL

1.23mL

24.54mL

4.91mL

2.45mL

Ciforadenant 技术信息

CAS号1202402-40-1
分子式C20H21N7O3
分子量 407.426
别名 CPI-444;V81444
运输蓝冰
存储条件

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度

DMSO: 65 mg/mL(159.54 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

Tags: Ciforadenant | CPI-444;V81444 | Adenosine Receptor | AmBeed-信号通路专用抑制剂 | Ciforadenant 纯度/质量文件 | Ciforadenant 亚型比较 | Ciforadenant 生物活性 | Ciforadenant 动物研究 | Ciforadenant 临床数据 | Ciforadenant 参考文献 | Ciforadenant 实验方案 | Ciforadenant 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z